TFF Pharmaceuticals Makes Available Phase 2 Data from Tacrolimus Inhalation Powder (TFF TAC) for the Prevention of Lung Transplant Rejection Presented at the Recent ISHLT Annual Meeting
TFF Pharmaceuticals, Inc. (TFFP)
Company Research
Source: GlobeNewswire
Data Now Available on Company Website Following 8-K Filing Data Demonstrate that Treatment with TFF TAC Prevents Lung Transplant Rejection at Only One-sixth of the Dose of Oral Tacrolimus and at Two-thirds of the Oral Tacrolimus Systemic Trough Exposures Gene Expression Biomarker Data Demonstrate that Treatment with TFF TAC Leads to Normalization of Expression of Rejection-Related Genes FORT WORTH, Texas, April 29, 2024 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP) (“the Company”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today announced that data from the Company’s ongoing Phase 2 trial of Tacrolimus Inhalation Powder (TFF TAC) for the prevention of lung transplant rejection is available on the Company’s website. These data were recently presented by Professor Gregory Snell, the lead Principal Investigator of the TFF TAC Phase 2
Show less
Read more
Impact Snapshot
Event Time:
TFFP
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TFFP alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TFFP alerts
High impacting TFF Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
TFFP
News
- TFF Pharmaceuticals Provides Update on Tacrolimus Inhalation Powder (TFF TAC) Phase 2 Trial for the Prevention of Lung Transplant Rejection [Yahoo! Finance]Yahoo! Finance
- TFF Pharmaceuticals Provides Update on Tacrolimus Inhalation Powder (TFF TAC) Phase 2 Trial for the Prevention of Lung Transplant RejectionGlobeNewswire
- TFF Pharmaceuticals Reports First Quarter Financial Results and Provides Corporate Update [Yahoo! Finance]Yahoo! Finance
- TFF Pharmaceuticals Reports First Quarter Financial Results and Provides Corporate UpdateGlobeNewswire
- TFF Pharmaceuticals Announces Closing of Pricing of $4.8 Million Public Offering [Yahoo! Finance]Yahoo! Finance
TFFP
Earnings
- 11/14/23 - Beat
TFFP
Sec Filings
- 5/14/24 - Form 8-K
- 5/14/24 - Form 10-Q
- 5/8/24 - Form SC
- TFFP's page on the SEC website